Last reviewed · How we verify
non-biological DMARDs
Non-biological DMARDs are small-molecule drugs that suppress the immune system by inhibiting intracellular signaling pathways to reduce inflammation and joint damage in autoimmune diseases.
Non-biological DMARDs are small-molecule drugs that suppress the immune system by inhibiting intracellular signaling pathways to reduce inflammation and joint damage in autoimmune diseases. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Psoriatic arthritis.
At a glance
| Generic name | non-biological DMARDs |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Non-biological DMARD (Disease-Modifying Antirheumatic Drug) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This class includes drugs like methotrexate, sulfasalazine, and leflunomide that work through various mechanisms such as inhibiting dihydrofolate reductase, blocking pyrimidine synthesis, or modulating T-cell activation. They reduce the proliferation of immune cells and decrease production of inflammatory cytokines, thereby slowing disease progression in rheumatoid arthritis and other autoimmune conditions.
Approved indications
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Psoriatic arthritis
- Ankylosing spondylitis
Common side effects
- Hepatotoxicity
- Bone marrow suppression
- Gastrointestinal disturbances
- Infection
- Rash
Key clinical trials
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines (PHASE3)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial (PHASE4)
- The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) (PHASE4)
- RA-PRO PRAGMATIC TRIAL (PHASE3)
- AScalate: Treat-to-target in Axial Spondyloarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- non-biological DMARDs CI brief — competitive landscape report
- non-biological DMARDs updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI